Neurocrine Biosciences News

SAN DIEGO, May 17, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure.

This report analyzes the worldwide markets for Endometriosis in US$ Million. The report provides separate comprehensive analytics for the US, , and Rest of World.

Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, Inc. , announced today at the A Deutsche Bank Securities 37th Annual Health Care Conference held at the Intercontinental Hotel in Boston that his company, which is partnering with Abbott Laboratories to develop a new treatment for endometriosis and other women's reproductive ... (more)

Hey, good morning everyone and thanks for attending the third and final day of the 37th Annual Deutsche Bank Health Care Conference.

SAN DIEGO, May 4, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Deutsche Bank 37th Annual Health Care Conference in Boston.

Good day everyone and welcome to Neurocrine Biosciences reports first quarter 2012 results.

SAN DIEGO, May 2, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2012.

BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Tuesday, May 1st 2012 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and December earnings reports.

Neurocrine Biosciences Inc. will unveil its latest earnings on Wednesday, May 2, 2012.